Literature DB >> 19329541

Higher TRIP-1 level explains diminished collagen contraction ability of fetal versus adult fibroblasts.

Angels Navarro1, Mo Rezaiekhaligh, J Andrew Keightley, Sherry M Mabry, Ricardo E Perez, Ikechukwu I Ekekezie.   

Abstract

Acute lung injury involving extremely immature lungs often heals without excessive fibrosis unlike later in gestation and in adults. Several factors may be involved, but fibroblast contraction of collagen has been linked to the level of wound fibrosis. To assess whether human lung fibroblasts of fetal versus adult origin differ in ability to contract collagen and define the molecular underpinnings, we performed three-dimensional collagen contraction assay, analyzed their differential mRNA profile, specifically for transforming growth factor-beta (TGF-beta) signaling pathway and extracellular matrix components, studied the cell response to TGF-beta in culture, and used two-dimensional gel electrophoresis followed by mass spectrometry to identify differences in their overall proteomes. Human lung fetal fibroblasts contracted the collagen matrix less than the adults. Smooth muscle actin expression did not differ. TGF-beta stimulation resulted in greater Smad3 phosphorylation in fetal compared with adults. mRNA and proteomic profiling reveal a number of TGF-beta pathways, ECM components, and cytoskeletal regulatory molecules are differentially expressed between the cell types. Of note is TGF-beta receptor interacting protein 1 (TRIP-1), which we show inhibits fibroblast collagen contraction and is higher in fetal than adult fibroblasts. We conclude that human lung fetal fibroblasts are less able to contract collagen than adult lung fibroblasts. The diminished ability is not due to impediment of Smad3 activation but rather, at least in part, due to their higher level of TRIP-1 expression. TRIP-1 is a novel modulator of fibroblast collagen contraction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329541     DOI: 10.1152/ajplung.00012.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Semaphorin 4A enhances lung fibrosis through activation of Akt via PlexinD1 receptor.

Authors:  Hai-Ying Peng; Wei Gao; Fa-Rong Chong; Hong-Yan Liu; J I Zhang
Journal:  J Biosci       Date:  2015-12       Impact factor: 1.826

2.  Concentration-dependent effects of transforming growth factor β1 on corneal wound healing.

Authors:  Lingyan Wang; Chun-Ying Ko; Erin E Meyers; Benjamin S Pedroja; Nadia Pelaez; Audrey M Bernstein
Journal:  Mol Vis       Date:  2011-11-02       Impact factor: 2.367

3.  TRIP-1 via AKT modulation drives lung fibroblast/myofibroblast trans-differentiation.

Authors:  Michael F Nyp; Angels Navarro; Mohammad H Rezaiekhaligh; Ricardo E Perez; Sherry M Mabry; Ikechukwu I Ekekezie
Journal:  Respir Res       Date:  2014-02-15

4.  Lung epithelial-specific TRIP-1 overexpression maintains epithelial integrity during hyperoxia exposure.

Authors:  Michael F Nyp; Sherry M Mabry; Angels Navarro; Heather Menden; Ricardo E Perez; Venkatesh Sampath; Ikechukwu I Ekekezie
Journal:  Physiol Rep       Date:  2018-03

5.  Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts.

Authors:  Henrique Bregolin Dias; Jarbas Rodrigues de Oliveira; Márcio Vinícius Fagundes Donadio; Shioko Kimura
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

6.  Cell morphology and mechanosensing can be decoupled in fibrous microenvironments and identified using artificial neural networks.

Authors:  Edward D Bonnevie; Beth G Ashinsky; Bassil Dekky; Susan W Volk; Harvey E Smith; Robert L Mauck
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

7.  Dynamic immune response characteristics of piglets infected with Actinobacillus pleuropneumoniae through omic.

Authors:  Rining Zhu; Hexiang Jiang; Jun Wang; Chuntong Bao; Haiyao Liu; Fengyang Li; Liancheng Lei
Journal:  AMB Express       Date:  2021-12-24       Impact factor: 3.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.